Premium
P4‐329: NOVEL PERFUSION MRI BIOMARKER APPLIED TO MILD COGNITIVE IMPAIRMENT
Author(s) -
Morgan Catherine A.,
Melzer Tracy R.,
Mutsaerts Henri JMM.,
Spriggs Meg J.,
Roberts Reece P.,
Addis Donna R.,
Kirk Ian J.,
Tippett Lynette J.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.07.152
Subject(s) - dementia , grey matter , neuropsychology , cerebral perfusion pressure , neuroimaging , memantine , medicine , cardiology , perfusion scanning , cognition , alzheimer's disease , psychology , neuropsychological assessment , audiology , cognitive decline , donepezil , white matter , perfusion , magnetic resonance imaging , neuroscience , disease , radiology
Background:18F-THK5351 has originally been developed as a tau imaging PET tracer to detect neurofibrillary tangles. However, FTHK5351 was recently reported to bind to monoamine oxidase B (MAO-B) wit a certain level of affinity. MAO-B is localized to astrocyte and its concentration increases with the process of gliosis. This study was to examine the potential power of F-THK5351 detecting astrogliosis as a marker of neurodgeneration. Methods:We studied 35 subjects, including clinically diagnosed frontotemporal lobar degeneration (FTLD, n1⁄45), progressive supranuclear palsy (PSP, n1⁄48), corticobasal degeneration (CBD, n1⁄45), argyrophilic grain disorders (AGD, n1⁄45), neurofibrillary tangle dominant dementia (NFTD, n1⁄42), Creuzfeldt Jacob disease (CJD, n1⁄41), hippocampal sclerosis (HS, n1⁄42), and cognitively normal healthy subjects (CN, n1⁄47). All the participants were examined by multitracer PETwith C-PiB, F-THK5351, F-FDG, as well as structural MRI. Results: Regional F-THK5351 accumulation was observed in the disease specific regions where the neurodegeneration is expected to take place such as frontotemporal cortices in FTLD, midbrain in PSP, subcortical white matter of pre-central gyrus in CBD, ambient gyrus in AGD, hippocampus in NFTD and HS, sucortical region with CJD. The accumulation pattern of FTHK5351 basically well corresponds to the regions with atrophy with structural MRI and/or hypometabolism with F-FDG, however, in most of the cases it appeared to be more specific distribution for underlying diseases. Conclusions:18F-THK5351 may be a useful additional marker for neurodegeneration by detecting gliosis. Further study is necessary to evaluate its sensitivity and time course in the disease progression.